Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 2/20 | 0.42 |
| ▸ | HPGDS | O60760 | 2/20 | 0.41 |
| ▸ | SCN2A | Q99250 | 4/20 | 0.40 |
| ▸ | NPY5R | Q15761 | 3/20 | 0.38 |
| ▸ | CNR2 | P34972 | 5/20 | 0.38 |
| ▸ | CNR1 | P21554 | 3/20 | 0.38 |
| ▸ | MAP3K8 | P41279 | 1/20 | 0.38 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.38 |
| ▸ | SSTR3 | P32745 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7143472 | 0.91 | SCN2A (0.48) | HPGDSSCN2ANPY5RCNR2CNR1 | |
| SCHEMBL7187293 | 0.90 | BACE1 (0.44) | BACE1HPGDSSCN2ANPY5RCNR2 | |
| SCHEMBL7179734 | 0.87 | BACE1 (0.47) | BACE1HPGDSSCN2ANPY5RCNR2 | |
| SCHEMBL7143626 | 0.85 | BACE1 (0.45) | BACE1HPGDSSCN2ANPY5RCNR2 | |
| SCHEMBL7140173 | 0.84 | BACE1 (0.43) | BACE1HPGDSSCN2ANPY5RCNR2 | |
| SCHEMBL7143623 | 0.84 | BACE1 (0.46) | BACE1HPGDSSCN2ANPY5RCNR2 | |
| SCHEMBL8110914 | 0.82 | CYP1A2 (0.44) | BACE1HPGDSSCN2ANPY5RCNR2 | |
| SCHEMBL7138024 | 0.82 | SSTR3 (0.47) | BACE1HPGDSSCN2ANPY5RMAPK14 | |
| SCHEMBL7135108 | 0.81 | CYP1A2 (0.46) | BACE1HPGDSSCN2ANPY5RCNR2 | |
| SCHEMBL7135105 | 0.80 | BACE1 (0.41) | BACE1HPGDSSCN2ANPY5RCNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6515133-B1 | Certain diaryl imidazoles act as partial agonists or antagonists for NPY receptors, in particular NPY 5 receptors. They are of use, for example in treating loss of appetite. Such compounds bear aryl groups in the 2 position. | NEUROGEN CORPORATION | 2003-02-04 | — | — | US | claimed |
| US-6515133-B1 | Certain diaryl imidazoles act as partial agonists or antagonists for NPY receptors, in particular NPY 5 receptors. They are of use, for example in treating loss of appetite. Such compounds bear aryl groups in the 2 position. | NEUROGEN CORPORATION | 2003-02-04 | — | — | US | disclosed |
| US-6121260-A | Method of treating conditions susceptible to modulation of NPY receptors with diarylimidazole derivatives | NEUROGEN CORPORATION (US) | 2000-09-19 | — | — | US | disclosed |